At a glance
- Originator Novartis
- Class Antihyperlipidaemics
- Mechanism of Action Sterol O-acyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
Most Recent Events
- 13 Feb 1995 No-Development-Reported for Hypercholesterolaemia in Switzerland (Unknown route)